---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-010245"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T09:49:27.452890+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ocugen FY2024 net loss $0.20; advances three gene therapy programs toward BLA filings

## Summary
- Q4 net loss $0.05/share; full-year net loss $0.20/share vs $0.26 in 2023.
- Cash $58.8M as of Dec 31, 2024; runway into Q1 2026; $65M financing secured in H2 2024.
- OCU400 Phase 3 RP enrollment on track for H1 2025; BLA/MAA target mid-2026.
- OCU410ST Stargardt Phase 2/3 pivotal trial FDA-aligned; BLA target 2027.
- OCU410 GA completed Phase 2 dosing; no serious adverse events; BLA target 2028.

## SEC filing metadata
- accession: 0001628280-25-010245
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/0001628280-25-010245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/ocgn-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-010245
- JSON: https://secwatch.observer/filing/0001628280-25-010245.json
- Plain text: https://secwatch.observer/filing/0001628280-25-010245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.